Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5668 in MUC16+ Malignancies
NCT04590326Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Nov 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of REGN5668 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), endometrial cancer (EC), sponsored by Regeneron Pharmaceuticals. Started Dec 2020; status: recruiting.
02
Drugs
REGN5668
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04590326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590326.